JPMorgan Chase & Co. grew its stake in shares of BeiGene, Ltd. (NASDAQ:BGNE) by 186.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 154,298 shares of the company’s stock after purchasing an additional 100,395 shares during the period. JPMorgan Chase & Co. owned about 0.17% of BeiGene worth $39,869,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Parallel Advisors LLC raised its stake in BeiGene by 35.0% during the 4th quarter. Parallel Advisors LLC now owns 135 shares of the company’s stock valued at $35,000 after purchasing an additional 35 shares during the period. Signaturefd LLC lifted its stake in BeiGene by 90.1% in the 4th quarter. Signaturefd LLC now owns 249 shares of the company’s stock worth $64,000 after acquiring an additional 118 shares in the last quarter. Marshall Wace North America L.P. acquired a new stake in BeiGene during the 1st quarter worth about $76,000. Fieldpoint Private Securities LLC purchased a new position in BeiGene during the 4th quarter valued at about $130,000. Finally, Vestmark Advisory Solutions Inc. increased its holdings in shares of BeiGene by 9.8% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 781 shares of the company’s stock valued at $202,000 after purchasing an additional 70 shares during the period. Institutional investors and hedge funds own 60.65% of the company’s stock.
Several equities analysts have recently commented on the stock. HSBC boosted their price target on shares of BeiGene from $296.00 to $385.00 and gave the company a “buy” rating in a report on Tuesday, March 16th. Zacks Investment Research raised BeiGene from a “sell” rating to a “hold” rating in a research report on Tuesday. CLSA lowered BeiGene from an “outperform” rating to an “underperform” rating and reduced their price target for the company from $330.00 to $321.00 in a report on Monday, March 1st. Morgan Stanley increased their price objective on BeiGene from $310.00 to $375.00 and gave the stock an “overweight” rating in a report on Tuesday, January 19th. Finally, Cowen lifted their target price on shares of BeiGene from $348.00 to $429.00 and gave the company an “outperform” rating in a research note on Thursday, February 25th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $318.56.
BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Thursday, February 25th. The company reported ($5.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.23) by ($0.97). BeiGene had a negative return on equity of 56.81% and a negative net margin of 569.22%. Sell-side analysts expect that BeiGene, Ltd. will post -17.91 earnings per share for the current fiscal year.
In other news, CMO Jane Huang sold 1,500 shares of the stock in a transaction that occurred on Friday, January 29th. The stock was sold at an average price of $322.99, for a total value of $484,485.00. Following the completion of the transaction, the chief marketing officer now directly owns 285,583 shares of the company’s stock, valued at approximately $92,240,453.17. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Howard Liang sold 12,600 shares of the business’s stock in a transaction on Friday, January 15th. The shares were sold at an average price of $344.90, for a total value of $4,345,740.00. Following the completion of the sale, the chief financial officer now directly owns 1,573,715 shares in the company, valued at approximately $542,774,303.50. The disclosure for this sale can be found here. Insiders have sold 15,600 shares of company stock worth $5,316,225 in the last quarter. Corporate insiders own 9.00% of the company’s stock.
BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).
Featured Story: Intrinsic Value
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.